Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,048 mentions
- robotic manipulationmarket834 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology492 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology372 mentions
- vision-language-action modeltechnology355 mentions
- agentic AItechnology353 mentions
- Vision-Language Modeltechnology321 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology176 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology170 mentions
- IBMorganization163 mentions
Entity
Entolasta
product8 mentionslast seen Nov 2, 2026
Next-generation TLR5 agonist designed for broader therapeutic applications including oncology supportive care.
Relationships 5
- Valion Bio, Inc.developsEntolasta99% confidence7 sources
- Entolastadepends onToll-like Receptor 5 agonist99% confidence4 sources
- Entolastaapplies tooncology supportive care99% confidence3 sources
- Entolastaapplies tocancer supportive care92% confidence1 source
- Entolastaapplies toradiation-induced neutropenia treatment85% confidence1 source
Relationship
Entolastadepends onToll-like Receptor 5 agonist
99% confidence4 supporting mentions
Either name opens that entity’s relationships.
Sources 4
- filingSEC EDGARNov 2, 2026Valion Bio, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion is also advancing Entolasta, a next-generation TLR5 agonist
- filingSEC EDGAROct 22, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolasta, a next-generation Toll-like receptor 5 ("TLR5") agonist
- filingSEC EDGAROct 15, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolasta, a next-generation TLR5 agonist
- filingSEC EDGAROct 1, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolasta, a next-generation TLR5 agonist